EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Efficacy of Rheocarna®, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia

Yoshimitsu Soga, Mitsuyoshi Takahara, Yasutaka Yamauchi, Osamu Iida, Masahiko Fujihara, Daizo Kawasaki, Kazunori Horie, Amane Kozuki, Tatsuro Takei, TURNIP Investigators

Circulation Journal · 25.04.2025 · 89 (5) · 557-565

DOI: 10.1253/circj.cj-24-0830 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Circulation Journal, erschienen am 25.04.2025. Verfasst von Yoshimitsu Soga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Kokura Memorial Hospital. Hauptthemen laut MEDLINE: Blood Component Removal, Chronic Limb-Threatening Ischemia, Ischemia, Peripheral Arterial Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although revascularization is first-line therapy for chronic limb-threatening ischemia (CLTI), there are no established treatments for patients in whom revascularization is not (or is a poor) option, including CLTI that has responded poorly to revascularization. This study verified the efficacy of the Rheocarna®, a novel apheresis device, for no-option CLTI or poor-response CLTI after revascularization. METHODS AND RESULTS: This multicenter retrospective observational study analyzed 221 patients (221 limbs) with no- or poor-option CLTI (mean [±SD] age 71±10 years; males, 70.1%; diabetes, 76.5%; dialysis, 87.8%; Rutherford category 6, 26.4%) undergoing apheresis with the Rheocarna between March 2021 and March 2022. The primary endpoint was the 1-year wound-healing rate. After apheresis with the Rheocarna, C-reactive protein, fibrinogen, and low-density lipoprotein cholesterol (LDL-C) levels decreased significantly, and the ankle-brachial index (ABI) and skin perfusion pressure (SPP) increased significantly (all P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Component RemovalChronic Limb-Threatening IschemiaIschemiaPeripheral Arterial DiseaseHumansMaleAgedFemaleRetrospective StudiesMiddle AgedAged, 80 and overWound HealingTreatment OutcomeFibrinogenCholesterol, LDLChronic DiseaseAnkle Brachial Index

Stichwörter der Autor:innen

Adjuvant therapyApheresisChronic limb-threatening ischemiaNo-option chronic limb-threatening ischemiaRevascularization

Substanzen

FibrinogenCholesterol, LDL

Autor:innen und Institutionen

  • Department of Cardiology, Kokura Memorial Hospital.
  • Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine.
  • Cardiovascular Center, Takatsu General Hospital.
  • Cardiovascular Division, Osaka International Medicine and Science Center.
  • Department of Cardiology, Kishiwada Tokushukai Hospital.
  • Department of Cardiology, Morinomiya Hospital.

Zitieren

APA

Soga, Y., Takahara, M., Yamauchi, Y., Iida, O., Fujihara, M., Kawasaki, D., Horie, K., Kozuki, A., Takei, T., & TURNIP Investigators (2025). Efficacy of Rheocarna®, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia. Circulation Journal, 89(5), 557-565. https://doi.org/10.1253/circj.cj-24-0830

Vancouver

Soga Y, Takahara M, Yamauchi Y, Iida O, Fujihara M, Kawasaki D, et al. Efficacy of Rheocarna®, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia. Circulation Journal. 2025;89(5):557-565. doi:10.1253/circj.cj-24-0830

BibTeX
@article{Soga2025,
  author = {Soga, Yoshimitsu and Takahara, Mitsuyoshi and Yamauchi, Yasutaka and Iida, Osamu and Fujihara, Masahiko and Kawasaki, Daizo and Horie, Kazunori and Kozuki, Amane and Takei, Tatsuro and TURNIP Investigators, TURNIP Investigators},
  title = {Efficacy of Rheocarna®, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia},
  journal = {Circulation Journal},
  year = {2025},
  volume = {89},
  number = {5},
  pages = {557--565},
  doi = {10.1253/circj.cj-24-0830}
}
Kostenlos starten →